# Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1

- Link: https://www.thailand-business-news.com/pr-news/peer-reviewed-publication-shows-that-lateral-pharmas-scp-drugs-for-neuropathic-pain-act-via-the-novel-target-lancl1
- Published: 2026-06-11T15:22:00+07:00
- Author: PR Newswire

MELBOURNE, Australia, June 11, 2026 /PRNewswire/ — Lateral Pharma today announced
the publication of peer-reviewed research in _PAIN_, a leading journal dedicated
to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as
a novel therapeutic target for neuropathic pain. The LanCL family of proteins are
responsive to Lateral Pharma’s Stressed Cell Protectant (SCP) drugs.

The publication, titled _"Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic
target for neuropathic pain,"_ shows that LAT8881, Lateral Pharma’s first-generation
SCP peptide and several other SCP peptides, act via LanCL1 and offers new insights
into the biology underlying neuropathic pain.

Painful Neuropathy caused by diabetes, injury, chemotherapy and some viral infections
affects hundreds of millions of people worldwide. Existing therapies provide no 
benefit in at least half of the patients and have dose-limiting side effects or 
tolerability concerns, highlighting the need for new approaches.

"This publication marks a pivotal milestone in advancing the biology of neuropathic
pain and in accelerating Lateral Pharma’s mission. Chronic neuropathic pain is a
distressing and debilitating condition that affects around 10% of the population.
By identifying LanCL1 as a novel therapeutic target and demonstrating drug activity
through this pathway, the research delivers compelling scientific validation for
Lateral Pharma’s Stressed Cell Protectant platform and its potential to address 
major unmet medical needs." said David Kenley, Chief Executive Officer of Lateral
Pharma.

The publication is consistent with Lateral Pharma’s Phase 1b study in patients with
chronic lumbar radicular pain (sciatica) that showed a single intravenous dose of
LAT8881 was safe and well tolerated while demonstrating clinically meaningful reductions
in provoked pain.

The findings also complement recently published research in _Mucosal Immunology_
demonstrating that LAT9997, Lateral Pharma’s lead SCP peptide, significantly improved
survival and reduced lung injury in preclinical models of influenza-associated bacterial
pneumonia. In that study, two intranasal doses of LAT9997 administered during the
early stages of influenza infection improved survival from 0% in control animals
to 85% in treated animals, highlighting the broader therapeutic potential of LanCL-
targeted therapies beyond neuropathic pain.

The growing body of evidence supporting SCP therapeutics is further reinforced by
Lateral Pharma’s intellectual property portfolio, including a United States Patent
and Trademark Office (USPTO) granted composition-of-matter patent covering LAT9997
for the treatment of neuropathic pain.

**About Lateral Pharma**

Lateral Pharma is an Australian biotechnology company developing a new class of 
therapeutics based on the activation of LanCL pathways involved in cellular protection,
repair and recovery. The Company is focused on addressing significant unmet medical
needs supported by positive data in models of neuropathic pain, neurodegeneration,
infectious respiratory disease and healthy longevity.

The publication was authored by researchers from Monash University, the University
of Warwick, the University of Bristol, Pacific Discovery Services, Evotec and Lateral
Pharma, and is now available online through _PAIN_.

**Publication**

Spanswick DC et al. _Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic
target for neuropathic pain._ PAIN. 2026.

[https://journals.lww.com/pain/fulltext/9900/lanthionine_synthetase_c_like_protein_1__lancl1__.1196.aspx](https://journals.lww.com/pain/fulltext/9900/lanthionine_synthetase_c_like_protein_1__lancl1__.1196.aspx)

**Related Publication**

West AC et al. _Short-course intranasal LAT9997 therapy limits post-influenza bacterial
pneumonia by recalibrating lung immunity._ Mucosal Immunology. 2026.

[https://doi.org/10.1016/j.mucimm.2026.01.008](https://doi.org/10.1016/j.mucimm.2026.01.008)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1 ](http://www.prnasia.com/story/archive/4981533_CN81533_0?rand=184833)
